IP Library Granted Patent US 9,403,843
Granted Patent B2
US 9,403,843 · App. 14/376,361 · Granted Aug 2, 2016

Cysteine protease inhibitors and uses thereof

Inventors: Gregory R. J. Thatcher (Chicago, IL); Isaac Thomas Schiefer (Chicago, IL); Ottavio Arancio (New York, NY); Mauro Fa (New York, NY)
Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
C07D495/04C07D303/48C07D403/12C07D405/12C07D409/12C07D417/12C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,403,843
App. No.
14/376,361
Granted
Aug 2, 2016
Kind
B2
Abstract

The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine protease inhibitors or compositions comprising novel cysteine protease inhibitors. In some embodiments, the cysteine protease inhibitors are calpain inhibitors.

Claims (78)

1. A compound of formula (I-a),

wherein,

R 1 is —CO 2 H or —CO 2 (C 1 -C 4 )-alkyl;

R 2 is hydrogen or —(C 1 -C 4 )-alkyl;

R 4 is —(CH 2 )-thiazolyl;

R 5 is —(C 1 -C 6 )-alkyl-R 6 , —(C 2 -C 5 )-alkenyl, —(C 2 -C 5 )-alkynyl, —(CH 2 ) n -aryl, or —(CH 2 ) n -heteroaryl, wherein said aryl or heteroaryl are substituted with one or more R 7 groups;

R 6 is —N(R 10 )C(O)R 8 or —N(R 10 )S(O) 2 R 8 ;

R 7 is independently halogen, —(C 1 -C 3 )-alkyl, aryl, methylenedioxyphenyl, —S(O) 2 N(R 10 ) 2 , or —S(O) 2 N(R 10 ) 2 , wherein said aryl is optionally substituted with one or more R 9 groups;

R 8 is —(C 1 -C 6 )-alkyl-R 11 or aryl, wherein aryl is optionally substituted with one or more R 9 groups;

R 9 is independently hydrogen, halogen, —(C 1 -C 4 )-alkyl, —(C 1 -C 4 )-haloalkyl, —(C 2 -C 4 )-alkynyl, CN, NO 2 , —S(O) 2 N(R 10 ) 2 , or

R 10 is independently hydrogen or —(C 1 -C 4 )-alkyl;

R 11 is hydrogen or

n is an integer from 0-4; and

p is an integer from 0-3.

2. The compound of claim 1 , wherein

R 1 is —CO 2 H or —CO 2 (C 1 -C 4 )-alkyl;

R 2 is hydrogen or —(C 1 -C 4 )-alkyl;

R 4 is

R 5 is —(C 1 -C 4 )-alkyl-R 6 , —(CH 2 ) n -aryl, or —(CH 2 ) n -heteroaryl, wherein said aryl or heteroaryl are substituted with one or more R 7 groups;

R 6 is —N(R 10 )C(O)R 8 or —N(R 10 )S(O) 2 R 8 ;

R 7 is independently halogen, —(C 1 -C 3 )-alkyl, aryl, methylenedioxyphenyl, —S(O) 2 N(R 10 ) 2 , or —S(O) 2 N(R 10 ) 2 , wherein said aryl is optionally substituted with one or more R 9 groups;

R 8 is —(C 1 -C 6 )-alkyl-R 11 or aryl, wherein aryl is optionally substituted with one or more R 9 groups;

R 9 is independently hydrogen, halogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 2 )-haloalkyl, —(C 2 -C 4 )-alkynyl, CN, NO 2 , —S(O) 2 N(R 10 ) 2 , or

R 10 is independently hydrogen or —(C 1 -C 4 )-alkyl;

R 11 is hydrogen or

n is an integer from 0-2; and

p is an integer from 0-1.

3. The compound of claim 1 , wherein

R 1 is —CO 2 H or —CO 2 (C 1 -C 4 )-alkyl;

R 2 is hydrogen or —(C 1 -C 4 )-alkyl;

R 5 is —(CH 2 ) n -aryl, or —(CH 2 ) n -heteroaryl, wherein said aryl or heteroaryl are substituted with one or more R 7 groups;

R 7 is independently halogen, —(C 1 -C 3 )-alkyl, aryl, methylenedioxyphenyl, —S(O) 2 N(R 10 ) 2 , or —S(O) 2 N(R 10 ) 2 , wherein said aryl is optionally substituted with one or more R 9 groups;

R 9 is independently hydrogen, halogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 2 )-haloalkyl, —(C 2 -C 4 )-alkynyl, CN, NO 2 , —S(O) 2 N(R 10 ) 2 , or

R 10 is independently hydrogen or —(C 1 -C 4 )-alkyl;

n is an integer from 0-2; and

p is an integer from 0-1.

4. The compound of claim 1 , wherein

R 1 is —CO 2 H or —CO 2 (C 1 -C 2 )-alkyl;

R 2 is hydrogen or —(C 1 -C 2 )-alkyl;

R 5 is —(CH 2 ) n -phenyl, or —(CH 2 ) n -heteroaryl, wherein said phenyl or heteroaryl are substituted with one or more R 7 groups;

R 7 is independently halogen, —(C 1 -C 3 )-alkyl, phenyl, methylenedioxyphenyl, —S(O) 2 N(R 10 ) 2 , or —S(O) 2 N(R 10 ) 2 , wherein said phenyl is optionally substituted with one or more R 9 groups;

R 9 is independently hydrogen, halogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 2 )-haloalkyl, —(C 2 -C 4 )-alkynyl, CN, NO 2 , —S(O) 2 N(R 10 ) 2 , or

R 10 is independently hydrogen or —(C 1 -C 2 )-alkyl;

n is an integer from 0-2; and

p is an integer from 0-1.

5. The compound of claim 1 , wherein

R 1 is —CO 2 H or —CO 2 (C 1 -C 2 )-alkyl;

R 2 is hydrogen or —(C 1 -C 2 )-alkyl;

R 5 is thiazolyl or —(CH 2 )-triazolyl, wherein said thiazolyl or triazolyl are substituted with an R 7 group;

R 7 is phenyl optionally substituted with one or more R 9 groups;

R 9 is independently halogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 2 )-haloalkyl, —(C 2 -C 4 )-alkynyl, CN, NO 2 , —S(O) 2 N(R 10 ) 2 , or

R 10 is independently hydrogen or —(C 1 -C 2 )-alkyl; and

p is an integer from 0-1.

6. The compound of claim 1 , wherein

R 1 is —CO 2 H or —CO 2 (C 1 -C 2 )-alkyl;

R 2 is hydrogen or —(C 1 -C 2 )-alkyl;

R 5 is thiazolyl or —(CH 2 )-triazolyl, wherein said thiazolyl or triazolyl are substituted with an R 7 group;

R 7 is phenyl optionally substituted with one or more R 9 groups;

R 9 is independently halogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 2 )-haloalkyl, —(C 2 -C 4 )-alkynyl, CN, NO 2 , —S(O) 2 N(R 10 ) 2 , or

R 10 is independently hydrogen or methyl; and

p is an integer from 0-1.

7. The compound of claim 1 , wherein

R 1 is —CO 2 H or —CO 2 (C 1 -C 2 )-alkyl;

R 2 is hydrogen;

R 5 is

R 7 is phenyl optionally substituted with one or more R 9 groups;

R 9 is independently halogen, —(C 1 -C 2 )-alkyl, —(C 1 -C 2 )-haloalkyl, —(C 2 -C 3 )-alkynyl, NO 2 , —S(O) 2 NH 2 , or

 and

p is an integer from 0-1.

8. The compound of claim 1 , wherein the compound is selected from

(2S,3S)-3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid;

(2S,3S)-3-((S)-1-(4-(4-ethynylphenyl)thiazol-2-ylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid;

(2S,3S)-3-((S)-1-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid; and

(2S,3S)-3-((S)-1-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid.

9. The compound of claim 1 , wherein the compound is selected from

(2S,3S)-3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid;

(2S,3S)-3-((S)-1-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid; and

(2S,3S)-3-((S)-1-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 13, 2017
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044207/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2015
From: SCHIEFER, ISAAC THOMAS; THATCHER, GREGORY R. J.
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 035099/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2015
From: ARANCIO, OTTAVIO; FA, MAURO
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 035099/0856 →
Continuity (2)
Provisional Application 61593664 · Feb 1, 2012
Related Publication 20150045393A1 · Feb 12, 2015